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Implementing Methods to Improve
Perioperative Hemostasis in the
Surgical and Trauma Settings
DEBORAH J. NEVELEFF; LARRY W. KRAISS, MDABSTRACT
Achieving perioperative hemostasis is vital to surgical success. Inadequate control of
bleeding is associated with serious adverse outcomes, including extended duration of
surgery, unanticipated blood transfusions, shock, infection, impaired wound healing,
longer hospital stays, and mortality. Appropriate clinical management of bleeding in the
surgical and trauma settings requires careful collaborative planning and coordination by
the entire perioperative team. Perioperative nurses, because of their strategic role in
patient care, must be familiar with risk factors for excessive bleeding and the funda-
mental roles of hemostatic agents, environmental temperature, and blood transfusion in
controlling bleeding in the surgical patient. Knowledge of the characteristics, safety,
efficacy, and costs of available topical hemostatic agents promotes their appropriate
selection in the OR. By incorporating evidence-based approaches into practice, periop-
erative nurses can support effective intraoperative hemostasis, thereby improving patient
outcomes. AORN J 92 (November 2010) 1-15. © AORN, Inc, 2010.
Key words: hemostasis, porcine gelatin, bovine collagen, oxidized regenerated
cellulose, polysaccharide spheres, bovine thrombin, pooled human thrombin,
recombinant thrombin, immune-mediated coagulopathy, fibrin sealant.Achieving perioperative hemostasis throughinternal mechanisms or clinical interven-tions is vital to surgical success. Inade-
quate control of bleeding is associated with seri-
ous adverse outcomes during and after a surgical
procedure, including unanticipated blood transfu-
sions and related risks of exposure to blood prod-
ucts, shock, infection, impaired wound healing,
and mortality.1-3 Hemostatic challenges in surgery
can vary based on the amount of blood loss, gen-
erally categorized as minimal bleeding, moderate-
yet-controlled bleeding, and uncontrolled bleeding
typical in trauma cases. Extended duration of sur-
doi: doi: 10.1016/j.aorn.2010.08.006
© AORN, Inc, 2010gery, longer hospital stays, and other care-related
issues associated with perioperative bleeding also
increase the costs of care.1-3
The continuum of care in the surgical and
trauma settings is managed by a multidisciplinary
team of surgeons, anesthesia care providers,
nurses, and technologists, the constitution of
which varies according to the type of surgery and
the clinical condition of the patient. Improving
hemostatic practices is notably relevant to periop-
erative nurses because of their strategic role in
patient care. Nurse responsibilities in the OR in-
clude maintenance of a sterile environment,
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equipment needs. Furthermore, perioperative
nurses frequently assist in the assessment of intra-
operative bleeding, handle and prepare topical
hemostatic agents, and order blood products when
necessary.
General aspects of intraoperative hemostasis
and the use of topical hemostatic agents are dis-
cussed in this article to advance education on
hemostatic practice in the surgical and trauma
settings. Given the array of available topical he-
mostatic agents and approved indications, there
may not be a single optimal agent choice in a
particular clinical scenario; however, some agents
may be clearly inappropriate in specific circum-
stances. Perioperative nurses, therefore, require
knowledge of individual risk factors for excessive
bleeding and of the safety, efficacy, and costs of
available topical hemostatic agents to facilitate
their appropriate selection during surgery. By in-
corporating evidence-based approaches into prac-
tice, perioperative nurses can support effective
intraoperative hemostasis, thereby improving pa-
tient outcomes.
PRINCIPLES OF COAGULATION
In patients with a functional coagulation cascade,
the process of coagulation is initiated with injury-
induced disruption to a blood vessel.3,4 Tissue
external to the blood vessel is exposed to blood
cells, endothelial cells, clotting factors, and other
substances that flow through the bloodstream.3,4
During primary hemostasis, platelets are activated
to adhere to the broken surface of the blood ves-
sel and to each other, forming a temporary plug.3,4
Clotting factors in the bloodstream are then acti-
vated, prompting a protein-based process known
as the coagulation cascade, in which thrombin
is generated to form fibrin.3,4 Ultimately, fibrin
mesh combines with the aggregated platelets to
stabilize the platelet plug and form a mechanical
fibrin clot at the bleeding site, which prevents
further blood loss.3,4
S4 AORN JournalThe coagulation cascade is a complex process
that involves multiple interactions and coagulation
factor activations, all of which are required for
proper coagulation function (Figure 1).5 Stated
simply, the coagulation cascade involves an in-
trinsic (ie, contact activation) pathway, measured
by partial thromboplastin time, or an extrinsic (ie,
tissue factor) pathway, measured by prothrombin
time.5 Either of these pathways can activate a
common pathway, whereby factor X, in the pres-
ence of factor V, is activated; prothrombin is sub-
sequently cleaved to release thrombin, which, in
turn, converts fibrinogen to fibrin.5,6
Patient conditions or environmental factors
may impede clot formation. Hemostasis can be
hindered by platelet abnormalities, such as throm-
bocytopenia, which is especially common among
oncology patients undergoing chemotherapy.3,4
Patients with renal failure have normal platelet
levels, but their platelet function is compromised
because of uremia.7 Platelet function also may be
impaired by antiplatelet medications, such as aspi-
rin, clopidogrel, or prasugrel, which are fre-
quently administered to reduce the risk of heart
attack and stroke or to treat peripheral artery dis-
ease.3,8 Clot inhibition also can be attributable to
an abnormality in the coagulation cascade associ-
ated with use of therapeutic anticoagulation medi-
cations, such as heparin or warfarin,3,8 and also
may occur in conjunction with sepsis, cirrhosis,
autoimmune disorders, or consumptive conditions
that have depleted the patient’s coagulation fac-
tors.3 Less commonly, a patient may have an in-
herited coagulation abnormality, such as von
Willebrand disease.9
Intraoperative hypothermia exemplifies an envi-
ronmental factor that inhibits clot formation be-
cause the coagulation cascade is less efficient at
lower temperatures.3,4 Hypothermia constitutes a
greater risk in patients with select preoperative
risk factors (eg, low body weight, advanced age,
low blood pressure, low heart rate)10 and is more
likely to occur in patients experiencing acute
blood loss.2 A meta-analysis of 14 studies that
NACCME SUPPLEMENT www.aornjournal.orgcompared blood loss and transfusion requirements
in more than 2,000 normothermic and mildly hy-
pothermic surgical patients revealed that less than
one degree of hypothermia increased blood loss
during surgery by 16% (P  .009) and increased
the risk of transfusion by 22% (P  .027).11 Fre-
quent monitoring of temperature and rewarming
measures may improve hypothermia-related pa-
tient outcomes.12
METHODS OF ACHIEVING HEMOSTASIS
Optimal hemostasis generally occurs when surgi-
cal technique controls all surgical sources of
bleeding and the patient’s own coagulation system
effectively seals microvascular sources of bleed-
ing. In this favorable situation, no additional he-
mostatic management is necessary; however, ideal
OR situations do not always transpire. Periopera-
tive measures should be focused on achievingsatisfactory hemostasis without resorting to trans-
fusion. Even when blood-product transfusion is
unavoidable, the amount that needs to be adminis-
tered may be minimized by implementing mea-
sures that reduce blood loss or that enhance the
patient’s own hemostatic mechanisms. Clinical
options include adequate surgical technique that
controls all discrete large vessel bleeding, atten-
tion to the physiologic state of the patient (eg,
temperature, pH), and the use of topical hemo-
static products.
Hemostasis challenges and associated interven-
tions vary in accordance with bleeding severity
(ie, minimal, moderate yet controlled, uncon-
trolled). Achieving local hemostasis can be ac-
complished through a variety of strategies; in
cases that involve minimal or moderate bleeding,
surgical teams may consider direct application of
AORN Journal S5
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mostasis may also be achieved endogenously by
allowing the patient’s physiologic system to reach
hemostasis naturally or by using supplemental
techniques of compression or packing.3
Select surgical or trauma situations may require
use of systemic hemostasis strategies. For exam-
ple, the surgical team can anticipate and reduce
bleeding problems in patients who are taking war-
farin by preoperatively administering vitamin K.3
Patients receiving heparin before surgery or re-
ceiving intentional intraoperative heparin adminis-
tration may require administration of protamine.3
When it is otherwise unavoidable, fresh frozen
plasma, cryoprecipitate, and platelets may be re-
placed via transfusion to reverse preoperative or
intraoperative coagulopathy.3 Factor VII, a clot-
ting factor that accelerates clot formation, can be
administered in crisis situations.3
In all cases, there is a consistent objective to
support hemostasis by maintaining the patient’s
normal body temperature.3 Low body temperature
can prevent blood from coagulating normally,
which underscores the role of the perioperative
nurse to closely monitor the patient’s temperature,
obtain and operate rewarming equipment, and
increase room temperature when necessary to pro-
mote hemostasis. Acid-base balance, or pH,
which is critical to the functioning of body sys-
tems, also can affect coagulation.3
Successful achievement of hemostasis through
mechanical or systemic methods can avert the
need for transfusion, which is associated with a
high risk of adverse clinical outcomes.1,2,13 A
prospective, multicenter, observational cohort
study of nearly 5,000 patients in intensive care
found that the number of red blood cell transfu-
sions a patient received during the study period
was independently associated with an extended
length of stay in the intensive care unit, a longer
total hospital length of stay, a greater number of
complications, and an increased risk of mortality.1
The leading cause of transfusion-related morbidity
and mortality is transfusion-related acute lung
S6 AORN Journalinjury, which occurs in approximately one of 500
platelet transfusions and one of 1,000 to 5,000
plasma and red blood cell transfusions.2,13 Other
leading causes of transfusion-related morbidity
and mortality include bacterial contamination of
platelets, which occurs in one of every 2,000 to
3,000 transfusions, as well as transfusion-related
immunomodulation and transfusion-associated
circulatory overload.2,13
Achieving and maintaining hemostasis is fur-
ther complicated in the trauma surgery setting,
during which hypothermia, acidosis, and coagu-
lopathy, typically known as the “lethal triad” of
trauma, interact in a vicious cycle to compromise
patient outcomes.14 Trauma patients are often hy-
pothermic on arrival to the surgical suite, which
exacerbates coagulopathy and interferes with he-
mostasis.14 Acidosis that results from hemor-
rhagic shock also promotes coagulopathy and im-
pairs blood clotting mechanisms.14 Hypothermia
and acidosis further potentiate coagulopathy, with
ongoing bleeding leading to continued hypother-
mia and acidosis.14 Perioperative nurses should
give special consideration to this subset of condi-
tions to effectively manage trauma patients. The
presence of these conditions tends to increase the
hemostatic challenge and may affect the choice of
adjunctive topical agent. As discussed in the fol-
lowing section, certain agents rely more than oth-
ers on the integrity of the patient’s own coagula-
tion cascade. In these more critical clinical
scenarios, the patient’s own coagulation system
may not be able to effectively contribute to the
formation of a clot.
TOPICAL HEMOSTASIS OPTIONS
Topical hemostats are agents that may allow sur-
gical teams to achieve hemostasis when tradi-
tional surgical methods are ineffective or inappro-
priate, but they are not a substitute for adequate
surgical technique. In other words, they will not
work effectively when the bleeding should be
controlled by suture or electrosurgery.15,16 Use
of topical hemostats may be indicated when the
NACCME SUPPLEMENT www.aornjournal.orgsurgical team is dealing with bleeding from dif-
fuse raw surfaces with a multitude of bleeding
points; bleeding close to the bone; bleeding
around delicate structures, including nerves;
bleeding in inaccessible locations; needle-hole
bleeding; and bleeding during laparoscopic or
robotic surgery.15,16
Various topical agents are available, and they
all fall into one of four categories:
 mechanical hemostats,
 active hemostats,
 flowables, and
 fibrin sealants.15
These types of agents vary in efficacy, the degree
to which they depend on the patient’s own coagu-
lation system for effectiveness, and cost.15
Mechanical Agents
Mechanical methods incorporate the topical
hemostat into an absorbable format, such as a
sponge or pad; options include porcine gelatin
(eg, Gelfoam®, Surgifoam®), bovine collagen (eg,
Avitene®, Helistat®), oxidized regenerated cellu-
lose (eg, Surgicel®), and microporous polysaccha-
ride spheres (eg, Arísta™).15 The efficacy of me-
chanical agents requires an intact coagulation
cascade to ensure that fibrin can ultimately be
produced after application of the mechanical
agent.6 Thus, these agents will not be effective
nor should they be relied on when hemorrhage is
caused by a significant coagulopathy. Mechanical
agents accelerate the coagulation cascade to pro-
mote time-sensitive control of bleeding, and effi-
cacy varies among products; bovine collagen is
typically the most efficacious, given that it also
activates platelets, followed by porcine gelatins,
polysaccharide spheres, and oxidized regenerated
cellulose.15 In general, the more efficacious
agents cost more.15
Mechanical agents are associated with certain
adverse effects, some of which the periopera-
tive nurse may be able to prevent or minimize.
Spotnitz and Burks15 have extensively addressed
the issues involved in the use of mechanical he-mostatic agents. Mechanical agents may require
up to six weeks to be fully absorbed, with the
exception of Arísta, which is absorbed within
48 hours.15 During the absorption process, the
presence of the foreign body in the wound can
predispose the patient to infection.15 Fluid absorp-
tion by the mechanical agent causes swelling and
underscores the need for meticulous agent place-
ment.15 For example, surgeons should avoid
placement in a small space adjacent to a nerve,
because swelling may cause impaired nerve func-
tion.15 Accordingly, mechanical agents should not
be placed proximate to the spinal foramina, where
nerve roots exit the spinal cord.15 If mechanical
agents must be used in small or sensitive areas,
then they should be removed by the end of the
surgical procedure.15 Likewise, the introduction of
a foreign body may inhibit skin or bone wound
healing. Mechanical agents should not be intro-
duced into the bloodstream, and perioperative
nurses should be aware of this warning when a
cell saver is being used.15 Finally, although some
mechanical agents can be safely combined with
thrombin, the acidity of cellulose may neutralize
the effectiveness of thrombin or other sealants by
altering the pH of the microenvironment.15 In
general, clinicians should use the smallest quan-
tity possible to achieve the desired effect.15
Active Agents (Topical Thrombin)
The three available active hemostatic agents,
outlined in Figure 2, are bovine thrombin (eg,
Thrombin-JMI®), pooled human plasma thrombin
(eg, Evithrom®), and recombinant thrombin (eg,
Recothrom®).6,15
The thrombins short-circuit the coagulation
cascade by adding the crucial enzymatic end
product directly to the bleeding site and enabling
topical thrombin cleavage of fibrinogen to pro-
duce the fibrin clot.6,15 Thrombins are practical
when the patient’s own coagulation system is
impaired because of heparinization, mild coagu-
lopathy, or other conditions.6,15 These agents are
unlikely to be effective as a stand-alone interven-
AORN Journal S7
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in patients with hypofibrinogenemia.15 Topical
thrombins are more effective than mechanical
hemostats at arresting local bleeding, but they are
also generally more expensive.15
The therapeutic use of thrombin has an exten-
sive history, with bovine thrombin first clinically
used by surgeons in World War II and the Korean
War.17,18 The US Food and Drug Administration
(FDA) officially granted approval of bovine
thrombin use in the 1970s; the product currently
on the market, Thrombin-JMI, received approval
in 1995.17,18 In 1996, however, the FDA required
manufacturers to include a black box warning on
the package insert regarding postoperative bleeding
after bovine thrombin use caused by activation of
the human immune system. The warning further
outlined the increased likelihood of antibody forma-
S8 AORN Journaltion with repeated use and advised against use in
patients who are taking antibodies.17,18 Two addi-
tional thrombin products were developed to circum-
vent the immunogenicity issue; the FDA approved
pooled human plasma thrombin in 2007 and recom-
binant thrombin in 2008.17,18
Bovine and pooled human plasma thrombin are
both derived from plasma, a complex mixture of
proteins. Bovine and human thrombin are purified
from plasma pools by using chromatography, then
activated to produce thrombin.19 The purification
procedure for bovine thrombin has been enhanced
to minimize undesirable bovine plasma proteins,
such as factor V, that activate the human immune
system.19 The human thrombin purification pro-
cess focuses on testing for and exclusion of po-
tentially transmissible infectious agents, such as
hepatitis viruses and HIV.19 Recombinant human
NACCME SUPPLEMENT www.aornjournal.orgthrombin is produced by using genetic techniques;
the human prothrombin gene is introduced into
Chinese hamster ovary cells, which then use their
own protein synthetic machinery to produce hu-
man prothrombin.20 During purification, the
thrombin precursor is cleaved to thrombin by
using a protease derived from snake protein.20
The approved thrombin products have demon-
strated comparative efficacy in achieving hemo-
stasis.16,21 For example, in a phase 3, double-
blind, comparative study, 401 patients were
randomly assigned to receive either recombinant
thrombin or bovine thrombin.16 Hemostasis was
achieved within 10 minutes in 95% of both pa-
tient groups.16 Similar results were obtained dur-
ing a head-to-head comparison of pooled human
thrombin with bovine thrombin.21
Clinicians should take special precautions when
administering topical thrombin, in particular, by
avoiding intravascular use of all thrombin products.
Thus, care should be taken to avoid uptake of these
products by a cell saver. Adverse effects are typi-
cally product specific. Bovine thrombin use is asso-
ciated with immunogenicity; therefore, repeated
doses are contraindicated.22 In the phase 3 trial pre-
viously discussed, 21.5% of patients to whom bo-
vine thrombin was administered exhibited immune
system activation, testing positive for antiproduct
antibodies by day 29, compared with 1.5% of pa-
tients to whom recombinant thrombin was adminis-
tered (P  .0001)16; the rates of immune system
activation in other studies range from 13% to
95%.16 As stated earlier, the package insert for bo-
vine thrombin includes a black box warning that
repeated applications increase the likelihood of anti-
body formation and that patients with antibodies to
bovine thrombin preparations should not be re-
exposed to these products.22 These precautions are
difficult to implement because a patient’s medical
record may not include all previous instances of
bovine thrombin exposure, and there is no clinically
available test to detect the presence of antibodies.
Approximately 60 cases of immune-mediated
coagulopathy related to bovine thrombin use havebeen reported in the past 20 years.23 Although there
is evidence that episodes of immune-mediated co-
agulopathy have decreased since 2000 with im-
proved purification methods,17 cases continued to be
reported as recently as 2008.24
Pooled human thrombin is associated with a
risk for transmission of infection.21 Human
thrombin is derived from large pools of human
plasma, with up to 60,000 donors represented per
lot of human thrombin.25 Despite extensive test-
ing of both donors and plasma for hepatitis A, B,
and C; HIV; and parvovirus, there is still a resid-
ual risk for hepatitis A and parvovirus infection
and a theoretical risk of variant Creutzfeldt-Jakob
disease caused by prion transmission.15,21,25
Recombinant thrombin has the theoretical
potential to cause allergic reactions attributable
to exposure of the product to hamster and
snake proteins during the manufacturing pro-
cess.20 Therefore, patients with a pre-existing
sensitivity to hamsters or snakes may be at
higher risk for an adverse reaction to recombi-
nant thrombin.20 During preoperative intake and
evaluation, it is appropriate for perioperative
nurses to ask patients about these sensitivities
as well as sensitivities to animal products used
to make mechanical hemostatic agents, such as
pork or beef.
Thrombin products vary in cost; in general,
bovine thrombin is least expensive, recombinant
thrombin is approximately 20% more expensive
than bovine thrombin, and pooled human throm-
bin is the most expensive thrombin product.
Prices will vary depending on specific purchasing
arrangements established by each hospital. For
example, average wholesale thrombin prices
quoted by the pharmacy at the University of
Utah, Salt Lake City (e-mail communication, Jan-
uary 2010), are as follows:
 Thrombin-JMI (bovine): $86.12 for 5,000
units/viral load (vL) and $339.65 for 20,000
units/vL;
AORN Journal S9
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international unit kit and $412.80 for 20,000
international unit kit; and
 Evithrom (pooled human): $691.20 for a 5-mL
vial and $2,587.50 for a 20-mL vial.
Flowables
Flowables (eg, FloSeal®, Surgiflo®) combine a
mechanical hemostat and an active hemostat into
a single application format.15 The products are a
mix of human plasma thrombin with either bovine
collagen gelatin or porcine collagen gelatin. Hu-
man plasma thrombin, which is typically reconsti-
tuted as a liquid and can thus run off the bleeding
surface, has a solid or pasty consistency when
combined with a gelatin.15 Therefore, flowable
hemostatic agents remain in place more effec-
tively than does the liquid thrombin alone.15
Clinical trials have demonstrated that flowables
are highly effective at achieving hemostasis.26,27
In a multicenter trial, 93 cardiac surgery patients
were randomly assigned to receive either FloSeal
or Gelfoam plus thrombin.26 Researchers found
that 94% of patients who received FloSeal exhib-
ited complete cessation of bleeding within 10
minutes compared with 60% of patients who re-
ceived Gelfoam® plus thrombin (P  .001).26 For
bleeding sites categorized as “heavy,” 77% of
patients who received FloSeal achieved hemosta-
sis at three minutes compared with 0% of patients
who received Gelfoam® plus thrombin (P 
.001).26 A multicenter, prospective, single-arm
study evaluated the hemostatic effectiveness of Surgiflo
in 30 patients undergoing revision endoscopic sinus
surgery for chronic sinusitis27; the researchers found
that 96.7% of patients achieved hemostasis within 10
minutes of product application, with a median total
time to hemostasis, including manual compression,
of 61 seconds.27
Fibrin Sealants
Fibrin sealants (eg, Tisseel®, Crosseal®, Hemas-
eel®, Evicel®) are effective in patients with co-
agulopathy who do not have sufficient fibrinogen
to form a clot.15,28 Fibrin sealants work by com-
S10 AORN Journalbining human thrombin with its target fibrinogen
in a single product to create fibrin.15,28 Active
bleeding is not necessary for fibrin sealants to be
effective.15,28 Fibrin sealants are multicomponent
products that contain fibrinogen, factor XIII,
thrombin, fibronectin, and ionized calcium.28 Tis-
seel also contains aprotinin, a bovine-derived anti-
fibrinolytic, to counteract fibrinolysis by plasmin.
Unlike Tisseel, Crosseal and Hemaseel are made
from human products, including concentrated hu-
man plasma and purified human thrombin, and
thus do not carry the risk of anaphylactic reaction
that Tisseel does, although they do carry the risk
of infectious disease transmission.28
Fibrin sealants are commonly used in open sur-
geries and are becoming more popular in control-
ling hemostasis in laparoscopic surgeries.28 Typi-
cally, fibrin sealants are used as adjunctive
therapy when thermal or chemical hemostatic
methods fail or are insufficient to achieve hemo-
stasis.28 Fibrin sealants, however, have been used
in laparoscopic surgery as a primary hemostatic
strategy.28 Preparation and administration of fibrin
sealants is more complicated than that of other
topical hemostats; the application system involves
two administration syringes, one that contains
thrombin and calcium and one that contains fi-
brinogen, fibronectin, and factor XIII,28 because
thrombin and fibrinogen must be separated until
immediately before application to the bleeding
site to prevent premature clot formation. Unlike
the other three fibrin sealants, Evicel is a frozen
liquid, but it requires less than one minute of
preparation time after thawing.28
Results of research studies have supported the
efficacy of fibrin sealants in achieving hemosta-
sis.29 In a multicenter trial, 121 patients undergo-
ing liver resection were randomly assigned to re-
ceive treatment with either Crosseal or another
standard topical hemostatic agent, such as Surgi-
cel or Gelfoam.29 The mean time to hemostasis
was 282 seconds with Crosseal compared with 468
seconds with standard agents (P  .06); hemostasis
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Experience-based anticipation and appropriate clinical management of bleeding in the surgical
and trauma settings can minimize the incidence of adverse outcomes associated with failure to
achieve hemostasis. Implementation of interventions for intraoperative bleeding requires careful
collaborative planning and coordination by the entire perioperative team. Appropriate and timely
response to transfusion reactions, shock, and infection can reduce mortality rates, length of stay,
and procedure-related costs.1 As essential members of the OR team, perioperative nurses require
familiarity with the fundamental roles of hemostatic agents, environmental temperature, and blood
transfusion in controlling bleeding in the perioperative patient.
Successfully used in a variety of medical, dental, and surgical settings since the 1970s, hemo-
static agents allow for local application of clotting factors to a bleeding site and control bleeding
by promoting the conversion of fibrinogen to fibrin.2,3 Because hemostatic agents are derived from
either bovine or human thrombin, associated risks include immunogenicity, foreign body responses,
infection, and impaired skin or bone wound healing.2,3 Problems with antibody development to
factor V and infectious disease have declined because of improvement in the production of human
thrombin and because of the development of recombinant human thrombin and fibrin preparations.2
Nursing involvement with agent use entails three primary responsibilities, the first of which is
preprocedural consultation with the surgeon regarding agents to be ordered to ensure the availabil-
ity of those agents in the surgical suite. Second, nurses assist with preparation and administration
of the agents as indicated. Finally, it is crucial for the nurse to document any and all administered
agents in the patient record because of the concern for antibody formation and anaphylaxis with
any repeated exposure, especially to bovine thrombin preparations.4 As a part of the follow-up pro-
cess, health care facility personnel are encouraged to provide a standardized letter to patients who
have received hemostatic agents that instructs them to share this medication history with future
health care providers.
Control of environmental temperature is another key strategy in the management of intraopera-
tive bleeding. Patients lose body heat from conductive, convective, evaporative, and radiative
mechanisms while they are in the surgical suite.2 Mild hypothermia is defined as a core body tem-
perature between 34° C and 36° C (93.2°F and 96.8° F); moderate hypothermia, between 32° C
and 34° C (89.6° F and 93.2° F); and severe hypothermia, lower than 32° C (89.6° F).2 Physio-
logic consequences of hypothermia include impaired oxygen delivery caused by a left shift of the
oxyhemoglobin dissociation curve, decreased cardiac output, increased risk of dysrhythmias, infec-
tion, electrolyte abnormalities, and coagulopathy.2 For each 1° C (1.8° F) drop in body tempera-
ture, there is a corresponding 10% decrease in coagulation factor activity.2 Since the mid-1980s,
clinical evidence has associated hypothermia with an increased risk of uncontrolled bleeding and
mortality, especially in trauma patients.2 Hypothermia-induced coagulopathies are multifactorial
and may be attributable to platelet dysfunction as a result of delayed response time, splenic seques-
tration, and altered morphology; the hypothermic liver does not produce coagulation enzymes.5
Furthermore, fibrinolysis is enhanced in the hypothermic setting.5,6 These conditions underscore
(continued)
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the crucial role of the perioperative nurse in maintaining an appropriate room temperature in the
operating suite, applying convective warming devices when practical, and using fluid warmers with
the administration of IV fluids and blood products.
A final discussion point germane to the management of perioperative hemostasis is the perioper-
ative nurse’s role in transfusion of blood and blood products. Specific blood products will be se-
lected by the anesthesiologist or the surgeon; however, the nurse is responsible for
 ordering the products,
 confirming their prompt delivery,
 helping to verify the received products against patient identification,
 assisting with agent preparation and administration, and
 assuring appropriate documentation.
Evolving experience in military settings may advance existing administration methods for tradi-
tional ratios of packed red blood cells, fresh frozen plasma, and even the use of fresh whole blood
in civilian practice in the coming years.7-10 The use of hemostatic adjuncts, such as recombinant
factor VIIa, antifibrinolytics, and plasma protein concentrate in massive transfusion scenarios may
change with the release of promising research results. Therefore, it behooves the nurse to be aware
of updates in transfusion practices, including the recently published red blood cell transfusion
guidelines for critical care.10 The perioperative team should review, discuss, and adapt evidence-
based recommendations to address the unique needs of its clinical environment.
1. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill—cur-
rent clinical practice in the United States. Crit Care Med. 2004;32(1):39-52.
2. Perkins JG, Cap AP, Weiss BM, Reid TJ, Bolan CD. Massive transfusion and nonsurgical hemostatic agents. Crit
Care Med. 2008;36(7 Suppl):S325-S339.
3. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;
48(7):1502-1516.
4. Thrombin-JMI [package insert]. Bristol, TN: King Pharmaceuticals, Inc; 2007.
http://www.kingpharm.com/products/product_document.cfm?brand_name
Thrombin%2DJMI&product_specific_name&document_type_codePI. Accessed August 12, 2010.
5. Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on co-
agulation enzyme activity and platelet function. J Trauma. 2004;56(6):1221-1228.
6. Gentilello LM, Jurkovich GJ, Stark MS, Hassantash SA, O’Keefe GE. Is hypothermia in the victim of major
trauma protective or harmful? A randomized, prospective study. Ann Surg. 1997;226(4):439-447.
7. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients
receiving massive transfusions at a combat support hospital. J Trauma. 2007;63(4):805-813.
8. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring mas-
sive transfusion. J Trauma. 2007;62(1):112-119.
9. Spinella PC. Warm fresh whole blood transfusion for severe hemorrhage: US military and potential civilian applications.
Crit Care Med. 2008;36(7 Suppl):S340-S345.
10. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult and
critical care. Crit Care Med. 2009;37(12):3124-3157.
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NACCME SUPPLEMENT www.aornjournal.orgwas achieved within 10 minutes in 91.4% of pa-
tients who received Crosseal compared with 69.8%
of patients treated with other topical hemostats (P 
.003).29 Furthermore, the percentage of patients that
developed postoperative complications was 17.2%
of patients who received Crosseal compared with
36.5% of patients who received a standard topical
hemostatic agent.29
CONCLUSION
As essential members of the surgical team,
perioperative nurses benefit from knowledge
regarding the various topical hemostats to facil-
itate selection of the most appropriate agent in
each case. Topical hemostatic agents, which
include mechanical hemostats, active hemostats
(ie, thrombins), flowables, and fibrin sealants,
vary in efficacy and adverse effect profiles. Op-
timal use of topical hemostats involves match-ing their efficacy with the magnitude of the
hemostatic challenge. That different topical he-
mostats interact with the coagulation cascade at
different levels is emphasized in Figure 3. Me-
chanical hemostats are most appropriate for
mild bleeding problems, whereas use of a fibrin
sealant in this instance would most likely be
unnecessary and not cost-effective. Reliance on
mechanical hemostats in the case of a profound
coagulopathy, however, would be ineffective
and likely a waste of time and opportunity; in
these situations, use of agents with more bio-
logic activity, such as fibrin sealants, is more
appropriate. Key concerns include
 immunogenicity associated with repeated bo-
vine thrombin use,
 appropriate placement of mechanical agents to
avoid nerve impairment caused by swelling,
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used in manufacturing recombinant thrombin,
and
 avoidance of uptake of mechanical and active
hemostats when cell savers are in use.
Perioperative nurses also play a valuable role in
monitoring and responding to hypothermia, which
impedes clot formation and increases the risk of
transfusion, and in identifying differences among
topical hemostats with regard to formulation, stor-
age, and preparation. By incorporating evidence-
based recommendations for the use of topical he-
mostats into practice, perioperative nurses
contribute to ensuring the safe and effective treat-
ment of surgical and trauma patients.
Editor’s note: Arísta is a trademark of Medafor,
Minneapolis, MN. Avitene is a registered trade-
mark of Davol, Warwick, RI. Crosseal is a regis-
tered trademark of Omrix Biopharmaceuticals,
Ltd, Ramat Gan, Israel. Evicel, Evithrom, Surgi-
cel, Surgiflo, and Surgifoam are registered trade-
marks of Ethicon, Inc, Somerville, NJ. FloSeal
and Tisseel are registered trademarks of Baxter
International, Inc, Deerfield, IL. Gelfoam is a
registered trademark of Pfizer, New York, NY.
Helistat is a registered trademark of Integra Life
Sciences Corp, Plainsboro, NJ. Hemaseel is a
registered trademark of Haemacure Corp, Mon-
treal, Quebec. Recothrom is a registered trade-
mark of ZymoGenetics, Seattle, WA. Thrombin-
JMI is a registered trademark of King
Pharmaceuticals, Bristol, TN.
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